Trial · NCT07473310
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
NCT07473310, Phase 4, Recruiting, Mansoura University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women. Trials, record NCT07473310. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07473310
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
- NCT number
- NCT07473310
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 70 participants, estimated
- Lead sponsor
- Mansoura University
- Conditions
- Overactive Bladder (OAB), Urge Incontinence
- Interventions
- Low intensity shockwave therapy, Oral Solifenacin succinate 5 mg
- First posted
- 2026-03-16
- Last updated
- 2026-03-16
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Overactive Bladder Symptom Score (OABSS) from baseline to different points of follow up | Baseline and 3 months | self administered questionnaire with minimum score of 0 and maximum score of 15, higher score means worse symptoms |
| Secondary | Changes in frequency on three-day urinary diary | from baseline to 1, 3, 6,9 and 12 months | Changes in the mean number of voiding episodes per days as measure by a self administered three-day urinary diary |
| Secondary | Changes in number of urgency episodes on three-day urinary diary | baseline to 1, 2, 3,6,9 and 12 months | Changes in the mean number of urgency episodes per day (strong desire to void that cannot be postponed or withheld) as measured by a self administered three-day voiding diary |
| Secondary | Changes in number of nocturia episodes on three-day urinary diary | baseline to 1, 2, 3,6,9 and 12 months | changes in the mean number of nocturia episodes per night(waking up in the middle of the night to void) as measured by a self-administered three-day voiding diary |
| Secondary | Changes in number of incontinence episodes on three-day urinary diary | form baseline to 1,2,3,6,9 and 12 months | Changes in number of incontinence episodes per day (involuntary leakage of urine) as measured by a self administered three-day urinary diary |
| Secondary | changes in International Consultation on Incontinence Questionnaire- Urinary Incontinence-Short Form (ICIQ-UI-SF) score | form baseline to 1,2,3,6,9 and 12 months | self administered questionnaire with minimum score of 0 and maximum score of 21, the higher score, the worse the symptoms |
| Secondary | changes in Overactive bladder quality of life questionnaire (ICIQ-OABqol) | from baseline to 1,2,3,6,9 and 12 months | self administered questionnaire with minimum score of 25 and maximum score of 160 , higher score indicated worse effect on the quality of life |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07473310
GET https://conductscience.org/api/trials/v1/NCT07473310/registered